DecisionGateway
Feed Claims Forecasts Trajectories Domains Calendar Actors Places Labs
Beta
API Sign in
HomeClaimsThis widens Foundayo's commercial lane beyond weight loss alone.
prediction

This widens Foundayo's commercial lane beyond weight loss alone.

A prediction by MY READ. Statements are as reported by the cited publishers — not verified by DecisionGateway.

This widens Foundayo's commercial lane beyond weight loss alone.
pattystraphousePublished 2026-11-09 Read source

Discussion

0/2000 Ctrl/⌘ + Enter

Related claims

Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.Eli Lilly · statementWhat changes this read: regulators reject the weight-loss-independent analysis, safety or adherence weakens in full publication, or payers restrict coverage despite an approval.MY READ · predictionLilly's analysis attributed 39.6% of the treatment effect to factors beyond weight loss.Lilly · statementAt 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus 3.6 with placebo.Lilly · statementThe FDA requires a warning about a risk of sudden blindness with popular weight-loss drugs.noticias_telemundo · statementVodafone raised its profit forecast after a cost cutting campaign.theedgesg · statement
All claims
FeedActorsForecasts